These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 39075482)

  • 1. Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.
    Chen X; Peng R; Peng D; Liu D; Li R
    J Transl Med; 2024 Jul; 22(1):701. PubMed ID: 39075482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Helicobacter pylori infection aggravates diet-induced nonalcoholic fatty liver in mice.
    He C; Cheng D; Wang H; Wu K; Zhu Y; Lu N
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):360-367. PubMed ID: 29657020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay between Helicobacter pylori infection and rs738409 PNPLA3 in metabolic dysfunction-associated steatotic liver disease.
    Maiorana F; Neschuk M; Caronia MV; Elizondo K; Robledo ML; Schneider A; Veron G; Zapata PD; Barreyro FJ
    PLoS One; 2024; 19(9):e0310361. PubMed ID: 39312529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BDE-47 induces metabolic dysfunction-associated steatotic liver disease (MASLD) through CD36-mediated increased fatty acid uptake and PPARα-induced abnormal fatty acid oxidation in BALB/c mice.
    Xia B; Yu R; Liu J; Liu D; Li S; Yang L; Liu N; Liang B; Zeng J; Wei J; Lin G
    Toxicol Lett; 2024 Jan; 391():100-110. PubMed ID: 38040069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid Trem2 ameliorates the progression of metabolic dysfunction-associated steatotic liver disease by regulating macrophage pyroptosis and inflammation resolution.
    Yu W; Zhang Y; Sun L; Huang W; Li X; Xia N; Chen X; Wikana LP; Xiao Y; Chen M; Han S; Wang Z; Pu L
    Metabolism; 2024 Jun; 155():155911. PubMed ID: 38609037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis.
    Mantovani A; Lando MG; Borella N; Scoccia E; Pecoraro B; Gobbi F; Bisoffi Z; Valenti L; Tilg H; Byrne CD; Targher G
    Liver Int; 2024 Jul; 44(7):1513-1525. PubMed ID: 38567962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zinc finger BED-type containing 3 promotes hepatic steatosis by interacting with polypyrimidine tract-binding protein 1.
    Wu Y; Yang M; Wu SB; Luo PQ; Zhang C; Ruan CS; Cui W; Zhao QR; Chen LX; Meng JJ; Song Q; Zhang WJ; Pei QQ; Li F; Zeng T; Du HX; Xu LX; Zhang W; Zhang XX; Luo XH
    Diabetologia; 2024 Oct; 67(10):2346-2366. PubMed ID: 39037604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cysteine-rich 61 inhibition attenuates hepatic insulin resistance and improves lipid metabolism in high-fat diet fed mice and HepG2 cells.
    Heo YJ; Park J; Lee N; Choi SE; Jeon JY; Han SJ; Kim DJ; Lee KW; Kim HJ
    FASEB J; 2024 Aug; 38(15):e23859. PubMed ID: 39082187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori infection worsens impaired glucose regulation in high-fat diet mice in association with an altered gut microbiome and metabolome.
    Peng C; Xu X; He Z; Li N; Ouyang Y; Zhu Y; Lu N; He C
    Appl Microbiol Biotechnol; 2021 Mar; 105(5):2081-2095. PubMed ID: 33576881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression.
    Wu LF; Zhou ZJ; Zeng YH; Yang SL; Zhang QY
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G485-G498. PubMed ID: 39259911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sex- and age-associated factors drive the pathophysiology of MASLD.
    Yadav AK; MacNeill JJ; Krylov A; Ashrafi N; Mimi RA; Saxena R; Liu S; Graham SF; Wan J; Morral N
    Hepatol Commun; 2024 Sep; 8(9):. PubMed ID: 39185904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helicobacter pylori colonization ameliorates glucose homeostasis in mice through a PPAR γ-dependent mechanism.
    Bassaganya-Riera J; Dominguez-Bello MG; Kronsteiner B; Carbo A; Lu P; Viladomiu M; Pedragosa M; Zhang X; Sobral BW; Mane SP; Mohapatra SK; Horne WT; Guri AJ; Groeschl M; Lopez-Velasco G; Hontecillas R
    PLoS One; 2012; 7(11):e50069. PubMed ID: 23166823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver matrin-3 protects mice against hepatic steatosis and stress response via constitutive androstane receptor.
    Cheng X; Baki VB; Moran M; Liu B; Yu J; Zhao M; Li Q; Riethoven JJ; Gurumurth CB; Harris EN; Sun X
    Mol Metab; 2024 Aug; 86():101977. PubMed ID: 38936659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-411-5p alleviates lipid deposition in metabolic dysfunction-associated steatotic liver disease by targeting the EIF4G2/FOXO3 axis.
    Wan Z; Liu X; Yang X; Huang Z; Chen X; Feng Q; Cao H; Deng H
    Cell Mol Life Sci; 2024 Sep; 81(1):398. PubMed ID: 39261317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice.
    Zou Z; Liu X; Yu J; Ban T; Zhang Z; Wang P; Huang R; Zheng F; Chang Y; Peng W; Tang Y; Feng X; Zhao Z; Lv X; Huang S; Guo J; Tuo Y; Zhou Z; Liang S
    J Hepatol; 2024 Jun; 80(6):834-845. PubMed ID: 38331323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocyte-specific Epidermal Growth Factor Receptor Deletion Promotes Fibrosis but has no Effect on Steatosis in Fast-food Diet Model of Metabolic Dysfunction-associated Steatotic Liver Disease.
    Bano S; Copeland MA; Stoops JW; Orr A; Jain S; Paranjpe S; Mooli RGR; Ramakrishnan SK; Locker J; Mars WM; Michalopoulos GK; Bhushan B
    Cell Mol Gastroenterol Hepatol; 2024; 18(4):101380. PubMed ID: 39038606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein mitigates diet-induced obesity and metabolic dysfunctions in gonadectomized mice with some sex-differential effects.
    Kositanurit W; Siritaweechai N; Varachotisate P; Burana C; Sukswai N; Surintrspanont J; Siriviriyakul P; Kaikaew K; Werawatganon D
    Front Endocrinol (Lausanne); 2024; 15():1392866. PubMed ID: 39351533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.